FDA announces labeling changes to opioid pain medications
The Food and Drug Administration July 31 announced that it is requiring safety label changes to all opioid pain medications to further emphasize and explain the risks associated with long-term use. The updates include presenting clearer risk information, stronger dosing warnings, clarified language on use limits, treatment guidance and more. Manufacturers were given 30 days to submit their labeling updates to the FDA for review.
Related News Articles
Headline
The Substance Abuse and Mental Health Services Administration has released a guide to improve coordination between 988 lifeline and 911 emergency services. It…
Headline
The latest estimates on overdose deaths released yesterday by the Centers for Disease Control and Prevention show that as of August 2025, deaths fell…
Headline
A Centers for Disease Control and Prevention report found a drastic increase in alcohol-related emergency department visits from 2003-2004 to 2021-2022. The…
Headline
President Trump Dec. 1 signed the AHA-supported SUPPORT Act (H.R. 2483) into law. The legislation reauthorizes key prevention, treatment and recovery programs…
Headline
A Health Affairs study published Nov. 3 examined an increase in states banning prior authorizations in private insurance plans for opioid use disorder…
Perspective
More than 48 million Americans — 16.8% of the 12-and-older population — have a substance use disorder (SUD), according to the 2025 National Survey on Drug Use…